VolitionRx (VNRX) said Wednesday it has entered into a collaboration with Japanese in-vitro diagnostics specialist Sysmex to optimize its Nu.Q NETs H3.1 assay on the Sysmex platform.

Financial terms of the collaboration were not provided.

The two companies have started the optimization phase of the test in diseases associated with NETosis, which is implicated in diseases such as sepsis, VolitionRx said.